Taiwan Stock Exchange · Healthcare
Excelsior Medical stock from India: price, numbers and tax
Excelsior Medical (4104) is not currently available to trade on Paasa; this guide covers the price, the numbers and the Indian tax treatment.
By Paasa · Updated
Excelsior Medical at a glance
- Price
- NT$72.70-NT$0.00 (0.00%)
- Market cap
- NT$13.69B
- Day range
- NT$72.30 – NT$72.70
- P/E
- 14.75
- Dividend yield
- 5.91%
- Volume
- 80.03K
- 1 month
- +2.25%
- 6 months
- -6.19%
- YTD
- -9.41%
- 1 year
- -15.47%
- 5 years
- +60.66%
Excelsior Medical statements, FY2021–FY2025
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | NT$8.8B | NT$8.5B | NT$8.2B | NT$7.2B | NT$6.6B |
| Gross profit | NT$1.9B | NT$1.8B | NT$1.7B | NT$1.5B | NT$1.4B |
| Operating income | NT$739.8M | NT$749.7M | NT$702.9M | NT$869.9M | NT$769.2M |
| Net income | NT$805.9M | NT$771.3M | NT$746.6M | NT$667.5M | NT$607.1M |
| Earnings per share | NT$4.62 | NT$4.48 | NT$4.57 | NT$4.08 | NT$3.71 |
| EBITDA | NT$1.0B | NT$1.2B | NT$968.6M | NT$1.2B | NT$1.1B |
| Total assets | NT$19.0B | NT$20.4B | NT$18.1B | NT$16.5B | NT$15.1B |
| Total debt | NT$2.2B | NT$1.4B | NT$1.4B | NT$808.5M | NT$762.4M |
| Cash and short-term investments | NT$3.5B | NT$4.9B | NT$3.4B | NT$3.2B | NT$3.8B |
| Shareholders' equity | NT$9.2B | NT$9.0B | NT$8.6B | NT$8.2B | NT$7.7B |
| Operating cash flow | −NT$1.2B | NT$2.5B | NT$107.1M | NT$637.1M | NT$945.0M |
| Free cash flow | −NT$1.3B | NT$2.4B | −NT$35.5M | NT$464.6M | NT$776.3M |
| Capital expenditure | −NT$77.8M | −NT$120.7M | −NT$126.4M | −NT$172.5M | −NT$168.8M |
Fiscal years as reported, the latest ending 31 Dec 2025. Figures in TWD; a dash means the provider reported nothing for that line.
Peer comparison
| Company | Ticker | Price | Market cap |
|---|---|---|---|
| Ever Supreme Bio Technology | 6712.TWO | $162.00 | $16.48B |
| Synmosa Biopharma | 4114.TWO | $29.50 | $15.92B |
| YungShin Global | 3705.TW | NT$56.70 | NT$15.10B |
| Visco Vision | 6782.TW | NT$237.50 | NT$14.96B |
| TaiDoc Technology | 4736.TW | NT$130.00 | NT$12.40B |
| TaiDoc Technology | 4736.TWO | $129.50 | $12.35B |
| Universal Vision Biotechnology | 3218.TWO | $134.00 | $11.35B |
| Great Tree Pharmacy | 6469.TWO | $64.40 | $9.66B |
Peers as grouped by the data provider. This is not an investment recommendation.
Why invest in Excelsior Medical from India
What Excelsior Medical does
Excelsior Medical Co., Ltd. operates as a distributor of a diverse range of healthcare technology and products throughout various Asian nations, specifically Taiwan, mainland China, Japan, South Korea, Malaysia, and the Philippines. Its extensive portfolio encompasses specialized machinery for hemodialysis, routine pharmaceuticals for healthcare facilities, surgical instrumentation, and electronic aids for medical professionals, in addition to cosmetic devices. Excelsior Medical operates in the Medical - Distribution industry within the Healthcare sector.
Paasa handles the paperwork
Investing abroad brings paperwork with it: remittance filings, capital gains reporting, foreign asset disclosure. Paasa prepares all of it for you. Your India-ready tax reports arrive at year end, ready to file.
Frequently asked questions
What tax do I pay in India when I sell Excelsior Medical shares?
In India, gains on shares held for more than 24 months are long-term and taxed at 12.5%, and gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. Both are worked out in rupees at the TWD/INR rate on the day you bought and the day you sold, so the currency move is part of the gain.